Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG099
MIFTS: 62

Lung Disease

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Disease

About this section

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 12 15 17
Lung Diseases 55 43 44 15 72

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:850
MeSH 44 D008171
NCIt 50 C3198
SNOMED-CT 68 19829001
ICD10 33 J60-J70 J98.4
UMLS 72 C0024115
Sources

Summaries for Lung Disease

About this section
MedlinePlus : 43 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Lung Disease, also known as lung diseases, is related to interstitial lung disease and pulmonary disease, chronic obstructive, and has symptoms including dyspnea, apnea and hemoptysis. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and Toll-like Receptor Signaling Pathway. The drugs Caspofungin and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.

Sources

Related Diseases for Lung Disease

About this section

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1236)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 34.9 TNF SFTPD SFTPC SFTPB MUC5B ITGA3
2 pulmonary disease, chronic obstructive 34.1 TNF SFTPD SFTPB SERPINA1 ELANE CXCL8
3 extrinsic allergic alveolitis 33.9 SFTPD IL1B IL10 CXCL8
4 pneumoconiosis 33.9 TNF SERPINA1 MUC5B IL1B CXCL8
5 alpha-1-antitrypsin deficiency 33.8 SERPINA1 ELANE CXCL8
6 idiopathic interstitial pneumonia 33.7 SFTPD SFTPC SFTPA2 SFTPA1 MUC5B ELANE
7 pulmonary fibrosis 33.7 TERT SFTPD SFTPC SFTPA2 SFTPA1 MUC5B
8 surfactant dysfunction 33.7 SFTPC SFTPB SFTPA1 ABCA3
9 silicosis 33.6 TNF SFTPD IL1B CXCL8
10 cystic fibrosis 33.6 SFTPD SERPINA1 ELANE CXCL8 CFTR
11 bronchopulmonary dysplasia 33.6 SFTPB ELANE CXCL8
12 bronchiolitis 33.5 TNF MUC5B IL10 CXCL8
13 aspergillosis 33.3 TNF SFTPD SFTPA2 IL10 ELANE CFTR
14 respiratory failure 33.3 TNF SFTPD SFTPC SFTPB SERPINA1 ELANE
15 bagassosis 33.3 IL1B CXCL8
16 pulmonary alveolar proteinosis 33.3 SFTPD SFTPC SFTPB
17 respiratory distress syndrome in premature infants 33.3 SFTPC SFTPB SFTPA1 ABCA3
18 allergic bronchopulmonary aspergillosis 33.3 SFTPD SFTPA2 CFTR
19 mycobacterium abscessus 33.3 TNF SERPINA1 CXCL8 CFTR
20 bronchiolitis obliterans 33.3 TNF IL10 CXCL8
21 pulmonary fibrosis, idiopathic 33.2 TNF TERT SFTPD SFTPC SFTPB SFTPA2
22 asthma 33.0 TNF IL1B IL10 ELANE CXCL8 CFTR
23 pneumonia 32.8 TNF SFTPD SFTPC SFTPB MUC5B IL1B
24 bronchiectasis 32.5 SERPINA1 ELANE CXCL8 CFTR
25 bronchitis 32.5 TNF SERPINA1 ELANE CXCL8 CFTR
26 haemophilus influenzae 32.0 TNF IL1B CXCL8
27 pulmonary emphysema 31.9 SFTPD SFTPC SERPINA1 ELANE
28 acute interstitial pneumonia 31.9 SFTPD SFTPA2 SFTPA1
29 acute respiratory distress syndrome 31.9 TNF SFTPD SFTPC SFTPB IL1B ELANE
30 pulmonary edema 31.7 TNF IL1B IL10 CXCL8 CFTR
31 bacterial pneumonia 31.7 SFTPD SFTPB ELANE CXCL8
32 sleep apnea 31.7 TNF IL1B CXCL8
33 chorioamnionitis 31.6 TNF IL1B ELANE CXCL8
34 arthritis 31.6 TNF IL1B IL10 CXCL8
35 perinatal necrotizing enterocolitis 31.6 TNF IL1B CXCL8
36 adult respiratory distress syndrome 31.5 TNF SFTPC SFTPB IL10 ELANE CXCL8
37 proteasome-associated autoinflammatory syndrome 1 31.5 TNF IL1B IL10 ELANE CXCL8
38 newborn respiratory distress syndrome 31.5 SFTPD SFTPC SFTPB IL1B ELANE CXCL8
39 vasculitis 31.4 TNF SERPINA1 ELANE
40 acquired immunodeficiency syndrome 31.4 TNF IL1B IL10
41 neonatal respiratory failure 31.4 SFTPC SFTPB ABCA3
42 bacterial infectious disease 31.4 TNF IL1B IL10 ELANE CXCL8 CFTR
43 colitis 31.4 TNF IL1B IL10 CXCL8
44 ulcerative colitis 31.4 TNF IL1B IL10 CXCL8
45 graft-versus-host disease 31.3 TNF IL1B IL10
46 peptic ulcer disease 31.3 TNF IL1B IL10 CXCL8
47 inflammatory bowel disease 31.2 TNF IL1B IL10 CXCL8
48 toxic shock syndrome 31.2 TNF IL1B IL10 CXCL8
49 chlamydia 31.2 TNF IL1B IL10 CXCL8
50 cytomegalovirus infection 31.1 TNF IL1B CXCL8

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease
Sources

Symptoms & Phenotypes for Lung Disease

About this section

UMLS symptoms related to Lung Disease:


dyspnea, apnea, hemoptysis, snoring, coughing, labored breathing

MGI Mouse Phenotypes related to Lung Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ABCA3 CFTR ELANE FLNA IFIH1 IL10
2 hematopoietic system MP:0005397 10.11 CFTR ELANE FLNA IFIH1 IL10 IL1B
3 immune system MP:0005387 10.07 CFTR ELANE FLNA IFIH1 IL10 IL1B
4 mortality/aging MP:0010768 10.03 ABCA3 CFTR ELANE FLNA IFIH1 IL10
5 neoplasm MP:0002006 9.5 ELANE IL10 IL1B ITGA3 SFTPC TERT
6 respiratory system MP:0005388 9.4 ABCA3 CFTR FLNA IL10 ITGA3 MUC5B
Sources

Drugs & Therapeutics for Lung Disease

About this section

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 827)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
2
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
3
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
4
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
5
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
6
Riociguat Approved Phase 4 625115-55-1
7
Ledipasvir Approved Phase 4 1256388-51-8 67505836
8
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
9
Fenoterol Approved, Investigational Phase 4 13392-18-2 3343
10
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
11
Phenylephrine Approved Phase 4 59-42-7 6041
12
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
13
Montelukast Approved Phase 4 158966-92-8 5281040
14
Propranolol Approved, Investigational Phase 4 525-66-6 4946
15
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
16
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
17
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
18
Simvastatin Approved Phase 4 79902-63-9 54454
19
Theophylline Approved Phase 4 58-55-9 2153
20
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
21
Norflurane Approved, Experimental Phase 4 811-97-2
22
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
23
Fosinopril Approved Phase 4 98048-97-6 55891
24
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
25
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
26
Meperidine Approved Phase 4 57-42-1 4058
27
Dobutamine Approved Phase 4 34368-04-2 36811
28
Bisoprolol Approved Phase 4 66722-44-9 2405
29
Celiprolol Approved, Investigational Phase 4 56980-93-9
30
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
31
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
32
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
33
Atorvastatin Approved Phase 4 134523-00-5 60823
34
Desflurane Approved Phase 4 57041-67-5 42113
35
Ergotamine Approved Phase 4 113-15-5 8223
36
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
37
Nortriptyline Approved Phase 4 72-69-5 4543
38
Prucalopride Approved Phase 4 179474-81-8
39
Bisacodyl Approved Phase 4 603-50-9
40
Histamine Approved, Investigational Phase 4 51-45-6 774
41 Ancrod Approved, Investigational Phase 4 9046-56-4
42
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
43
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
44
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
45
Cetirizine Approved Phase 4 83881-51-0 2678
46
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
47
Clarithromycin Approved Phase 4 81103-11-9 84029
48
Morphine Approved, Investigational Phase 4 57-27-2 5288826
49
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
50
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 4641)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin Unknown status NCT00132860 Phase 4 azithromycin
3 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
4 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
5 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
6 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
7 Acute Effect of Recombinant Human Brain Natriuretic Peptide in Patients With Pulmonary Hypertension Associated With Acute Exacerbation of Chronic Pulmonary Disease Unknown status NCT02742909 Phase 4 rhBNP;placebo
8 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
9 Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD Unknown status NCT00288548 Phase 4 Metoprolol
10 An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
11 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
12 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
13 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
14 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
15 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
16 Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System Unknown status NCT01460108 Phase 4
17 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial Unknown status NCT02197871 Phase 4
18 Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD. Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
19 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype Unknown status NCT01431625 Phase 4
20 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
21 Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
22 A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
23 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
24 The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
25 The Lung Attack Alert Study Unknown status NCT01107613 Phase 4
26 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
27 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
28 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
29 Targeting of the Small Airways in Patients With COPD: Airway Effects of Tiotropium - Respimat vs Handihaler Unknown status NCT02683668 Phase 4
30 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD：a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
31 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
32 Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery - a Randomized, Blinded, Placebo Controlled Study Unknown status NCT02576223 Phase 4 Ropivacaine hydrochloride;Isotonic Saline
33 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
34 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
35 The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
36 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
37 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
38 Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
39 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
40 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
41 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
42 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
43 Evaluation and Treatment of Small Airways in COPD Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
44 A Multicentre, Randomized, Clinical Trial of Noninvasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure - NINAVAPed Protocol Unknown status NCT01873521 Phase 4
45 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
46 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
47 Advair - CRP Study Unknown status NCT00120978 Phase 4 Advair;Flovent
48 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
49 Phase IV Study of the Quantiferon-RD1 Test Unknown status NCT00311220 Phase 4 tuberculin for skin test
50 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Sources

Genetic Tests for Lung Disease

About this section
Sources

Anatomical Context for Lung Disease

About this section

MalaCards organs/tissues related to Lung Disease:

41
Lung, Testes, Heart, Neutrophil, Bone, Endothelial, T Cells
Sources

Publications for Lung Disease

About this section

Articles related to Lung Disease:

(show top 50) (show all 42030)
# Title Authors PMID Year
1
ELOM-080 as Add-On Treatment for Respiratory Tract Diseases - A Review of Clinical Studies Conducted in China. 17
31167299 2019
2
Facing the challenges of perioperative air leaks using water seal in Colombia. 17
31126190 2019
3
Nasal High-Flow Therapy for Newborn Infants in Special Care Nurseries. 17
31116919 2019
4
Decreased Cyp2E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. 9 38
20514434 2010
5
Characteristics of disorders associated with genetic mutations of surfactant protein C. 9 38
20403820 2010
6
Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. 9 38
20230362 2010
7
Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. 9 38
20404089 2010
8
Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. 9 38
20511978 2010
9
Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. 9 38
20082309 2010
10
Long-term stability and circadian variation in circulating levels of surfactant protein D. 9 38
19540617 2010
11
Nrf2 protects against airway disorders. 9 38
19646463 2010
12
The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. 9 38
20423679 2010
13
Lack of correlation between pulmonary disease and cystic fibrosis transmembrane conductance regulator dysfunction in cystic fibrosis: a case report. 9 38
20420703 2010
14
Assessment of alveolar epithelial permeability with Tc-99m DTPA aerosol scintigraphy in patients with Sjogren syndrome. 9 38
19582462 2010
15
Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. 9 38
20448817 2010
16
Airway proteins involved in bacterial clearance susceptible to cathepsin G proteolysis. 9 38
19679607 2010
17
Alpha1-antitrypsin deficiency: forgotten etiology. 9 38
20090075 2010
18
Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. 9 38
19762563 2010
19
Clara cell secretory protein in tracheobronchial aspirates and umbilical cord serum of extremely premature infants with systemic inflammation. 9 38
19887851 2010
20
Development of carbohydrate-derived inhibitors of acid sphingomyelinase. 9 38
20005726 2010
21
4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. 9 38
19904934 2010
22
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 9 38
20082271 2010
23
TNFalpha-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. 9 38
19850966 2009
24
Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. 9 38
19603002 2009
25
Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. 9 38
19759179 2009
26
Early subcutaneous administration of etanercept (Enbrel) prevents from hyperoxia-induced lung injury. 9 38
19916860 2009
27
Surfactant protein C in canine pulmonary fibrosis. 9 38
19747194 2009
28
Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. 9 38
19797509 2009
29
Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. 9 38
19443536 2009
30
alpha1-Antitrypsin deficiency: best clinical practice. 9 38
19783716 2009
31
Methemoglobin to cumulative nitric oxide ratio and response to inhaled nitric oxide in PPHN. 9 38
19554014 2009
32
Histone deacetylase-2 and airway disease. 9 38
19812111 2009
33
Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. 9 38
19375295 2009
34
Long-acting local anesthetics attenuate FMLP-induced acute lung injury in rats. 9 38
19690261 2009
35
Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. 9 38
19242722 2009
36
Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. 9 38
19251783 2009
37
Matrix metalloproteinase-9 deficiency worsens lung injury in a model of bronchopulmonary dysplasia. 9 38
19097983 2009
38
New surfactant protein C gene mutations associated with diffuse lung disease. 9 38
19443464 2009
39
Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. 9 38
19596921 2009
40
Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. 9 38
19372250 2009
41
IL1B polymorphisms modulate cystic fibrosis lung disease. 9 38
19431193 2009
42
Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. 9 38
19349911 2009
43
Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. 9 38
19329540 2009
44
Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3. 9 38
19292764 2009
45
[Diagnosis and prediction of lung cancer through different classification techniques with tumor markers]. 9 38
19538834 2009
46
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. 9 38
19242412 2009
47
Generation of bleomycin-induced lung fibrosis is independent of IL-16. 9 38
19232499 2009
48
Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. 9 38
19466271 2009
49
Exhaled nitric oxide levels in alpha-1-antitrypsin PiMZ subjects. 9 38
19019191 2009
50
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. 9 38
19707397 2009
Sources

Variations for Lung Disease

About this section
Sources

Expression for Lung Disease

About this section
Search GEO for disease gene expression data for Lung Disease.
Sources

Pathways for Lung Disease

About this section

Pathways related to Lung Disease according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Metabolism of proteins 66
Show member pathways
 13.68 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 SERPINA1
2
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13.02 TNF SFTPD SFTPA2 IL1B IL10 CXCL8
3
IL-17 Family Signaling Pathways 65
Show member pathways
 12.24 TNF MUC5B IL1B CXCL8 CFTR
4
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.18 TNF TERT IL1B IL10 CXCL8
5
IL-1 Family Signaling Pathways 65
Show member pathways
 12.14 TNF MUC5B IL1B CXCL8 CFTR
6
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.09 TNF IL1B IL10 CXCL8
7
Bacterial infections in CF airways 22
Show member pathways
 12.02 TNF SFTPD SFTPA1 IL1B CXCL8 CFTR
8
Interleukin-4 and 13 signaling 66
11.91 TNF IL1B IL10 CXCL8
9
AGE-RAGE signaling pathway in diabetic complications 37
11.83 TNF IL1B CXCL8
10
NF-kappa B signaling pathway 37
11.83 TNF IL1B CXCL8
11
Amoebiasis 37
11.83 TNF IL1B IL10 CXCL8
12
Hematopoietic cell lineage 37
11.81 TNF ITGA3 IL1B
13
Rheumatoid arthritis 37
11.78 TNF IL1B CXCL8
14
Diseases of metabolism 66
Show member pathways
 11.73 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
15
Salmonella infection (KEGG) 37
11.72 IL1B FLNA CXCL8
16
Innate Lymphoid Cell Differentiation Pathways 65
11.71 TNF IL1B IL10
17
Dendritic Cells Developmental Lineage Pathway 65
11.67 TNF IL1B IL10
18
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.64 TNF IL1B IL10
19
Pertussis 37
11.61 TNF SFTPA2 SFTPA1 IL1B IL10 CXCL8
20
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.59 TNF IL1B CXCL8
21
Legionellosis 37
11.52 TNF IL1B CXCL8
22
Malaria 37
11.45 TNF IL1B IL10 CXCL8
23
Interleukin-10 signaling 66
11.42 TNF IL1B IL10 CXCL8
24
FOXA1 transcription factor network 1
Show member pathways
 11.37 SFTPD SFTPA2 SFTPA1 SERPINA1
25
African trypanosomiasis 37
11.3 TNF IL1B IL10
26
IL-10 Pathway 64
11.29 TNF IL1B IL10
27
Cytokines and Inflammatory Response 1
11.17 TNF IL1B IL10
28
G-protein signaling_RhoB regulation pathway 22
11.13 TNF IL1B IL10 CXCL8
29
Lung fibrosis 1
11.08 TNF TERT SFTPC SFTPA2 SFTPA1 SERPINA1
30
Surfactant metabolism 66
Show member pathways
 11.07 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 ABCA3
31
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5) 66
Show member pathways
 10.95 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
32
G-protein signaling_Rap2B regulation pathway 22
10.94 TNF ITGA3 IL1B IL10 CXCL8
Sources

GO Terms for Lung Disease

About this section

Cellular components related to Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1
2 endoplasmic reticulum membrane GO:0005789 9.95 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 CFTR
3 collagen trimer GO:0005581 9.63 SFTPD SFTPA2 SFTPA1
4 multivesicular body GO:0005771 9.62 SFTPD SFTPB SFTPA2 SFTPA1
5 rough endoplasmic reticulum GO:0005791 9.61 SFTPD SFTPA2 SFTPA1
6 multivesicular body lumen GO:0097486 9.4 SFTPC SFTPB
7 alveolar lamellar body GO:0097208 9.37 SFTPB ABCA3
8 lamellar body GO:0042599 9.26 SFTPC SFTPB SFTPA2 SFTPA1
9 clathrin-coated endocytic vesicle GO:0045334 9.02 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
10 extracellular region GO:0005576 10.07 TNF SFTPD SFTPC SFTPB SFTPA2 SFTPA1

Biological processes related to Lung Disease according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.93 TNF IL1B IL10 CXCL8
2 defense response to bacterium GO:0042742 9.92 TNF SFTPD IL10 ELANE
3 leukocyte migration GO:0050900 9.89 TNF ITGA3 IL1B ELANE
4 cellular response to lipopolysaccharide GO:0071222 9.86 TNF IL1B IL10 CXCL8
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 TNF TERT IL10
6 cellular protein metabolic process GO:0044267 9.7 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 SERPINA1
7 toll-like receptor signaling pathway GO:0002224 9.67 SFTPD SFTPA2 SFTPA1
8 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.65 TNF TERT IL1B
9 response to molecule of bacterial origin GO:0002237 9.62 IL10 CXCL8
10 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.61 TNF ELANE
11 positive regulation of chemokine biosynthetic process GO:0045080 9.61 TNF IL1B
12 endothelial cell apoptotic process GO:0072577 9.6 TNF IL10
13 regulation of establishment of endothelial barrier GO:1903140 9.58 TNF IL1B
14 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL1B
15 response to glucocorticoid GO:0051384 9.58 TNF IL10 ABCA3
16 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 TNF IL10
17 positive regulation of fever generation GO:0031622 9.54 TNF IL1B
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.54 TNF IL1B IL10
19 sequestering of triglyceride GO:0030730 9.52 TNF IL1B
20 negative regulation of growth of symbiont in host GO:0044130 9.5 TNF IL10 ELANE
21 receptor biosynthetic process GO:0032800 9.46 TNF IL10
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IL1B
23 surfactant homeostasis GO:0043129 9.43 SFTPD SFTPA2 SFTPA1
24 positive regulation of phagocytosis GO:0050766 9.35 TNF SFTPD SFTPA2 SFTPA1 IL1B
25 chronic inflammatory response to antigenic stimulus GO:0002439 9.21 TNF
26 respiratory gaseous exchange GO:0007585 9.02 SFTPD SFTPC SFTPB SFTPA2 SFTPA1

Molecular functions related to Lung Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 TNF IL1B IL10 CXCL8
2 lipopolysaccharide binding GO:0001530 9.33 SFTPD SFTPA2 SFTPA1
3 protease binding GO:0002020 9.26 TNF SERPINA1 ITGA3 ELANE
4 monosaccharide binding GO:0048029 8.8 SFTPD SFTPA2 SFTPA1
5 protein binding GO:0005515 10.19 TNF TERT SFTPD SFTPC SFTPA1 SERPINA1
Sources

Sources for Lung Disease